{"denoms":[{"counts":[{"groupId":"BG000","value":"133"},{"groupId":"BG001","value":"22"},{"groupId":"BG002","value":"155"}],"units":"Participants"}],"groups":[{"description":"Participants were administered valemetostat tosylate at a dose of 200 mg/day and had an eligible peripheral T-cell lymphoma .","id":"BG000","title":"Cohort 1: Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)"},{"description":"Participants were administered valemetostat tosylate at a dose of 200 mg/day and had an eligible adult T-cell leukemia/lymphoma.","id":"BG001","title":"Cohort 2: Relapsed/Refractory Adult T-cell Leukemia/Lymphoma"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"63"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"92"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"12.51","value":"65.6"},{"groupId":"BG001","spread":"13.11","value":"62.6"},{"groupId":"BG002","spread":"12.60","value":"65.2"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"49"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"106"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"42"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"16"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"81"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"15"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"The Safety Analysis Set included all subjects who received at least 1 dose of study drug. Subjects were analyzed for each cohort."}